Takeda chief executive officer, christophe weber, commented Takeda pharmaceutical has announced it will discontinue all cell therapy research and development, marking a significant strategic withdrawal from a field it once considered a priority area for innovation. “takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of.
Speed - Hailie Deegan continues to make social media drool after leaked photos of her in a tiny
What's going on at takeda pharmaceutical (nyse:tak)
Read today's tak news from trusted media outlets at marketbeat.
Takeda pharmaceutical (tse:4502) shares have seen subtle moves recently, and investors are weighing the outlook as the market absorbs ongoing developments in japan’s pharmaceutical sector See our latest analysis for takeda pharmaceutical Takeda’s shares have kept investors guessing this year, with momentum pausing despite upbeat clinical. For more information, visit www.takeda.com
